{
    "Trade/Device Name(s)": [
        "iLet\u00ae Dosing Decision Software"
    ],
    "Submitter Information": "Beta Bionics, Inc.",
    "510(k) Number": "K232224",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220916"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "September 22, 2023",
    "Summary Letter Received Date": "July 27, 2023",
    "Submission Date": "July 26, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Blood glucose"
    ],
    "Specimen Type(s)": [
        "Capillary blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Compatible integrated continuous glucose monitors (iCGM)",
        "Alternate controller enabled (ACE) pumps",
        "Self-monitoring of blood glucose (SMBG) meter"
    ],
    "Method(s)/Technology(ies)": [
        "Automated glycemic control algorithm",
        "Adaptive basal/bolus/meal insulin controllers"
    ],
    "Methodologies": [
        "Insulin titration algorithm",
        "Glucose-based dosing decision software"
    ],
    "Submission Type(s)": [
        "Software",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for iLet Dosing Decision Software, an interoperable automated glycemic controller for management of type 1 diabetes mellitus",
    "Indications for Use Summary": "Intended for autonomous management of insulin dosing based on iCGM input for type 1 diabetes mellitus in people 6 years of age or older; supports ACE pumps and manual blood glucose input when iCGM unavailable.",
    "fda_folder": "Clinical Chemistry"
}